99 892名多囊卵巢综合征北欧女性与446 055名对照者的2型糖尿病前瞻性风险:丹麦、芬兰和瑞典全国队列研究
这项基于丹麦、芬兰和瑞典全国登记的前瞻性队列研究纳入99 892名多囊卵巢综合征(PCOS)女性和446 055名年龄匹配对照,发现PCOS患者2型糖尿病(T2D)粗风险比为4.64(95%CI 3.40-5.87),校正BMI和教育年限后为2.92(95%CI 2.32-3.51),BMI≥30 kg/m2与<25 kg/m2相比T2D风险增加7.6至11.3倍。
要点
- PCOS女性T2D前瞻性风险升高,合并粗HR 4.64(95%CI 3.40-5.87)。
- 校正BMI和教育年限后合并HR为2.92(95%CI 2.32-3.51)。
- BMI≥30 vs <25 kg/m2与T2D风险增加7.6至11.3倍相关。
核心结论
- PCOS女性T2D诊断的前瞻性风险升高,且BMI≥30 kg/m2者的风险进一步加重。
研究设计与样本
- 全国登记为基础的队列研究,纳入PCOS女性99 892名和年龄匹配对照446 055名,来自丹麦、芬兰和瑞典。
- 主要结局为PCOS诊断后发生的T2D诊断,T2D依据ICD-10诊断编码和/或排除二甲双胍的抗糖尿病药物处方定义。
- 丹麦PCOS 27 016名、对照133 994名;芬兰PCOS 20 467名、对照58 051名;瑞典PCOS 52 409名、对照254 010名。
- PCOS女性入组中位年龄在丹麦、芬兰和瑞典均为28岁,中位随访时间(四分位距)分别为8.5(4.0-14.8)年、9.8(5.1-15.1)年和6.0(2.0-10.0)年。
- 采用Cox回归分析,校正BMI和教育年限。
主要发现
- PCOS女性T2D诊断的粗HR(95%CI)在丹麦为4.28(3.98-4.60),芬兰为3.40(3.11-3.74),瑞典为5.68(5.20-6.21)。
- 校正回归分析中,BMI≥30 vs <25 kg/m2与T2D风险增加7.6至11.3倍相关。
- 合并Meta分析(PCOS 99 892名,对照446 055名)中,PCOS患者T2D粗HR为4.64(3.40-5.87)。
- 校正BMI和教育水平后,合并HR为2.92(2.32-3.51)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究设计纳入较重PCOS病例,可能导致暴露人群风险估计高估。
- 对照组中部分女性可能存在未诊断的PCOS,可能导致PCOS女性T2D风险低估。
- BMI数据并非所有参与者均可获得。
- 本研究应在T2D背景风险更高的人群中重复,尤其是其他族裔人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the prospective risk of Type 2 diabetes (T2D) in Nordic women with polycystic ovary syndrome (PCOS) compared to controls? SUMMARY ANSWER: A diagnosis of PCOS and BMI ≥30 kg/m2 is a high-risk phenotype for a prospective risk of T2D diagnosis across Nordic countries. WHAT IS KNOWN ALREADY: The risk of T2D in women with PCOS is increased. The risk of T2D is related to BMI and the magnitude of risk in normal weight women with PCOS has been discussed. However, prospective data regarding risk of T2D in population-based cohorts of women with PCOS are limited. STUDY DESIGN, SIZE, DURATION: This national register-based study included women with PCOS and age-matched controls. The main study outcome was T2D diagnosis occurring after PCOS diagnosis. T2D was defined according to ICD-10 diagnosis codes and/or filled medicine prescriptions of anti-diabetic medication excluding metformin. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study cohort included women originating from Denmark (PCOS Denmark, N = 27 016; controls, N = 133 994), Finland (PCOS Finland, N = 20 467; controls, N = 58 051), and Sweden (PCOS Sweden, N = 52 409; controls, N = 254 010). The median age at cohort entry was 28 years in PCOS Denmark, Finland, and Sweden with a median follow-up time (interquartile range) in women with PCOS of 8.5 (4.0-14.8), 9.8 (5.1-15.1), and 6.0 (2.0-10.0) years, respectively. Cox regression analyses were adjusted for BMI and length of education. MAIN RESULTS AND THE ROLE OF CHANCE: The crude hazard ratio (HR, 95% CI) for T2D diagnosis in women with PCOS was 4.28 (3.98-4.60) in Denmark, 3.40 (3.11-3.74) in Finland, and 5.68 (5.20-6.21) in Sweden. In adjusted regression analyses, BMI ≥30 vs <25 kg/m2 was associated with a 7.6- to 11.3-fold risk of T2D. In a combined meta-analysis (PCOS, N = 99 892; controls, N = 446 055), the crude HR for T2D in PCOS was 4.64 (3.40-5.87) and, after adjustment for BMI and education level, the HR was 2.92 (2.32-3.51). LIMITATIONS, REASONS FOR CAUTION: Inclusion of more severe cases of PCOS in the present study design could have lead to an overestimation of risk estimates in our exposed population. However, some women in the control group would have undiagnosed PCOS, which would lead to an underestimation of T2D risk in women with PCOS. BMI data were not available for all participants. The present study should be repeated in study cohorts with higher background risks of T2D, particularly in populations of other ethnicities. WIDER IMPLICATIONS OF THE FINDINGS: The prospective risk for diagnosis of T2D is increased in women with PCOS, and the risk is aggravated in women with BMI ≥30 kg/m2. STUDY FUNDING/COMPETING INTEREST(S): Funding in Denmark was from the Region of Southern Denmark, Overlægerådet, Odense University Hospital. Funding in Finland was from Novo Nordisk Foundation, Finnish Research Council and Sigrid Juselius Foundation, the National Regional Fund, Sakari Alhopuro Foundation and Finnish Diabetes Research Foundation. E.E. has received a research grant from Ferring Pharmaceuticals (payment to institution) and serves as medical advisor for Tilly AB, not related to this manuscript. The remaining authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Glintborg D, Ollila MM, Møller JK, et al. Prospective risk of Type 2 diabetes in 99 892 Nordic women with polycystic ovary syndrome and 446 055 controls: national cohort study from Denmark, Finland, and Sweden. Hum Reprod. 2024. PMID: 38859639. doi:10.1093/humrep/deae124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。